Kronos Bio Highlights Preclinical Data At AACR Symposium Supporting Istisociclib Clinical Evaluation In Advanced Ovarian Cancer, Showing Efficacy In Platinum And PARP-Inhibitor Resistant Models
Kronos Bio Highlights Preclinical Data At AACR Symposium Supporting Istisociclib Clinical Evaluation In Advanced Ovarian Cancer, Showing Efficacy In Platinum And PARP-Inhibitor Resistant Models
kronos bio在AACR研討會上重點介紹了對愛文思控股卵巢癌臨床評估支持的Istisociclib預臨床數據，在鉑金和PARP抑制劑耐藥模型中展示出高效
Kronos Bio Highlights Preclinical Data At AACR Symposium Supporting Istisociclib Clinical Evaluation In Advanced Ovarian Cancer, Showing Efficacy In Platinum And PARP-Inhibitor Resistant Models
kronos bio在AACR研討會上重點介紹了對愛文思控股卵巢癌臨床評估支持的Istisociclib預臨床數據，在鉑金和PARP抑制劑耐藥模型中展示出高效
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間